...
tlsi-img

TriSalus Life Sciences Inc., Common Stock

TLSI

NMQ

$3.576

-$0.18

(-4.79%)

1D
Industry: Health Care Equipment & Supplies Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$114.65M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
40.02K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.50
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$3.5 L
$10.42 H
$3.576

About TriSalus Life Sciences Inc., Common Stock

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. more

Industry: Health Care Equipment & SuppliesSector: Health Care

Returns

Time FrameTLSISectorS&P500
1-Week Return-9.32%-3.35%-2.97%
1-Month Return-12.62%-3.49%-0.66%
3-Month Return-21.57%-12.6%2.71%
6-Month Return-36.62%-6.91%7.21%
1-Year Return-54.55%1.19%23.04%
3-Year Return-63.75%-0.21%28.43%
5-Year Return-65.78%33.09%82.88%

Financials

Dec '21Dec '22Dec '23
Total Revenue8.40M12.40M18.51M[{"date":"2021-12-31","value":45.38,"profit":true},{"date":"2022-12-31","value":66.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue1.19M2.26M2.60M[{"date":"2021-12-31","value":45.8,"profit":true},{"date":"2022-12-31","value":86.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit7.21M10.14M15.91M[{"date":"2021-12-31","value":45.32,"profit":true},{"date":"2022-12-31","value":63.75,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin85.80%81.79%85.93%[{"date":"2021-12-31","value":99.85,"profit":true},{"date":"2022-12-31","value":95.18,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses31.24M46.58M70.06M[{"date":"2021-12-31","value":44.59,"profit":true},{"date":"2022-12-31","value":66.49,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(24.03M)(36.44M)(54.15M)[{"date":"2021-12-31","value":-2403200000,"profit":false},{"date":"2022-12-31","value":-3643900000,"profit":false},{"date":"2023-12-31","value":-5415000000,"profit":false}]
Total Non-Operating Income/Expense(6.57M)(10.56M)(4.46M)[{"date":"2021-12-31","value":-657100000,"profit":false},{"date":"2022-12-31","value":-1056000000,"profit":false},{"date":"2023-12-31","value":-446400000,"profit":false}]
Pre-Tax Income(28.84M)(47.18M)(59.03M)[{"date":"2021-12-31","value":-2884200000,"profit":false},{"date":"2022-12-31","value":-4717800000,"profit":false},{"date":"2023-12-31","value":-5902900000,"profit":false}]
Income Taxes3.00K9.00K9.00K[{"date":"2021-12-31","value":33.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(28.84M)(47.19M)(59.04M)[{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}]
Income From Continuous Operations(28.84M)(47.19M)(59.04M)[{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}]
Income From Discontinued Operations---[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(28.84M)(47.19M)(59.04M)[{"date":"2021-12-31","value":-2884500000,"profit":false},{"date":"2022-12-31","value":-4718700000,"profit":false},{"date":"2023-12-31","value":-5903800000,"profit":false}]
EPS (Diluted)0.150.18(1.87)[{"date":"2021-12-31","value":83.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1039.06,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

TLSI
Cash Ratio 1.14
Current Ratio 2.40
Quick Ratio 2.00

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

TLSI
ROA (LTM) -133.15%
ROE (LTM) -496.21%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

TLSI
Debt Ratio Lower is generally better. Negative is bad. 1.74
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.74

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

TLSI
Trailing PE NM
Forward PE NM
P/S (TTM) 4.64
P/B 30.29
Price/FCF NM
EV/R 4.72
EV/Ebitda NM

FAQs

What is TriSalus Life Sciences Inc. share price today?

TriSalus Life Sciences Inc. (TLSI) share price today is $3.576

Can Indians buy TriSalus Life Sciences Inc. shares?

Yes, Indians can buy shares of TriSalus Life Sciences Inc. (TLSI) on Vested. To buy TriSalus Life Sciences Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TLSI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of TriSalus Life Sciences Inc. be purchased?

Yes, you can purchase fractional shares of TriSalus Life Sciences Inc. (TLSI) via the Vested app. You can start investing in TriSalus Life Sciences Inc. (TLSI) with a minimum investment of $1.

How to invest in TriSalus Life Sciences Inc. shares from India?

You can invest in shares of TriSalus Life Sciences Inc. (TLSI) via Vested in three simple steps:

  • Click on Sign Up or Invest in TLSI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in TriSalus Life Sciences Inc. shares
What is TriSalus Life Sciences Inc. 52-week high and low stock price?

The 52-week high price of TriSalus Life Sciences Inc. (TLSI) is $10.42. The 52-week low price of TriSalus Life Sciences Inc. (TLSI) is $3.5.

What is TriSalus Life Sciences Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of TriSalus Life Sciences Inc. (TLSI) is

What is TriSalus Life Sciences Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of TriSalus Life Sciences Inc. (TLSI) is 30.29

What is TriSalus Life Sciences Inc. dividend yield?

The dividend yield of TriSalus Life Sciences Inc. (TLSI) is 0.00%

What is the Market Cap of TriSalus Life Sciences Inc.?

The market capitalization of TriSalus Life Sciences Inc. (TLSI) is $114.65M

What is TriSalus Life Sciences Inc.’s stock symbol?

The stock symbol (or ticker) of TriSalus Life Sciences Inc. is TLSI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top